--News Direct--
Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share guidance for the company’s second-quarter that reveal it is heading for the sixth straight quarter of record revenue.
The company said it expects 2Q revenue to exceed $13.5 million while its adjusted underlying (EBITDA) loss will decrease to below $2 million as the company heads to profitability.
Saviuk told Proactive the number continues to be driven by Asthma medications ENERZAIR and ATECTURA which saw quarterly revenues grow 270% over this time last year. In fact, the total number of prescribing physicians also grew and is now expected to exceeds 2,000.
Contact Details
Proactive Investors
+1 347-449-0879
na-editorial@proactiveinvestors.com
View source version on newsdirect.com: https://newsdirect.com/news/valeo-pharma-2q-results-show-same-form-as-1q-with-guidance-revealing-record-quarterly-revenue-745479485
